To nullify modifications made by the Food and Drug Administration on January 3, 2023, to the risk evaluation and mitigation strategy under section 505-1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1) for mifepristone, and for other purposes.

HR 5850 nullifies a January 2023 FDA modification to the safety requirements for mifepristone, a medication used in medical abortions. The bill prohibits federal funding for implementing any similar safety requirements or enforcement policies for mifepristone. This directly affects how the drug can be distributed and accessed, as it reverses the FDA's updated risk management rules. The law aims to prevent federal support for any new restrictions on mifepristone access beyond the pre-January 2023 standards.